News

Men with ANCA-associated vasculitis (AAV) presenting kidney inflammation are more likely than women to progress into end-stage renal disease, according to Norwegian researchers. Their study, “Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study,” was published in the journal…

Tapazole (methimazole), a thyroid medication used to treat Graves’ disease, may in rare cases cause ANCA-associated vasculitis (AAV), a new patient study suggests. While the link between thyroid drugs and AAV is relatively common, few cases triggered by Tapazole have been described, and little is known about how…

In patients with ANCA-associated vasculitis (AAV), the reappearance of ANCA autoantibodies may work as a biomarker for predicting relapse, a new study suggests. Routine monitoring of ANCA antibody levels should be implemented in AAV patients in remission as a means to determine their risk of relapse, according to Japanese…

The protein myeloperoxidase (MPO) may increase the activation of neutrophils — key immune cells in ANCA-associated vasculitis — and heighten vascular injury in patients, a new study shows. The study, “Myeloperoxidase influences the complement regulatory activity of complement factor H,” was published in the journal Rheumatology. ANCA-associated vasculitis (AAV)…